684270-66-4

Upstream product

• 5845-53-4 (R)-leucine methyl ester hydrochloride 
• 1694-92-4 2-Nitrobenzenesulfonyl chloride 

Downstream Products

• 684270-67-5 N-(3-hydroxypropyl)-N-(2-nitrophenylsulfonyl)-D-leucine methyl ester 
• 391641-32-0 (2S,αR)-2-(4-methoxyphenyl)-α-(2-methylpropyl)-2-oxo-1,3,2-oxazaphosphorinane-3-acetic acid 
• 391641-31-9 (2R,αR)-2-(4-methoxyphenyl)-α-(2-methylpropyl)-2-oxo-1,3,2-oxazaphosphorinane-3-acetic acid 
• 391640-52-1 methyl (2S,αR)-2-(4-methoxyphenyl)-α-(2-methylpropyl)-2-oxo-1,3,2-oxazaphosphorinane-3-acetate 
• 391640-51-0 methyl (2R,αR)-2-(4-methoxyphenyl)-α-(2-methylpropyl)-2-oxo-1,3,2-oxazaphosphorinane-3-acetate 

Relevant academic research and scientific papers

Rhodium-Catalyzed Enantioselective Synthesis of Oxazinones via an Asymmetric Ring Opening-Lactonization Cascade of Oxabicyclic Alkenes

The rhodium-catalyzed asymmetric ring opening reaction of oxabicyclic alkenes is shown to be an efficient method for synthesizing chiral heterocycles. We demonstrate that the pairwise combination of chiral catalyst with chiral amino-acid-derived pronucleophiles results in a stereodivergent synthesis of diastereomeric hydroxyesters. A favorable conformational preference induces the subsequent lactonization of one diastereomer leading to the highly enantioselective synthesis of oxazinones.

Cyclic phosphinamides and phosphonamides, novel series of potent matrix metalloproteinase inhibitors with antitumour activity

The design, synthesis, and structure-activity relationship (SAR) of a series of novel nonpeptidic cyclic phosphon- and phosphinamide-based hydroxamic acids as inhibitors of matrix metalloproteinases MMP-1, MMP-3, and MMP-9 are presented. Based on modellin